IRADIMED Announces Special Cash Dividend of $0.50 Per Share
iRadimed (NASDAQ: IRMD) announced a special cash dividend of $0.50 per share, payable on December 30, 2025 to stockholders of record at the close of business on December 17, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iRadimed (NASDAQ: IRMD) announced a special cash dividend of $0.50 per share, payable on December 30, 2025 to stockholders of record at the close of business on December 17, 2025.
The Board said the dividend follows strong financial results, including 17 consecutive quarters of record revenue and a cash and cash equivalents balance of $56.5 million at the end of Q3 2025. Management cited excess cash beyond needs for operations and the transition to a new manufacturing facility, and noted ongoing investments such as commercialization of the 3870 MRI IV pump.
The Board emphasized future dividends remain at its sole discretion and are subject to financial condition, cash flows, capital requirements and other factors.
Positive
- Special dividend of $0.50 per share declared
- Cash and cash equivalents of $56.5 million at end of Q3 2025
- 17 consecutive quarters of record revenue
Negative
- One-time dividend reduces available cash for near-term uses
- No assurance the company will continue regular or special dividends
Details
News Market Reaction – IRMD
On Dec 8, the day this news came out, IRMD closed 0.96% above the previous close.
Data tracked by StockTitan Argus for the Dec 8 session.
Key Figures
- Special dividend
- $0.50 per share
- Declared by Board; payable December 30, 2025
- Dividend payable date
- December 30, 2025
- Special cash dividend payment date
- Record date
- December 17, 2025
- Holders of record for $0.50 special dividend
- Cash & equivalents
- $56.5 million
- Balance at end of Q3 2025 cited as excess cash
- Record revenue streak
- 17 consecutive quarters
- Quarters of record revenue highlighted by management
- Regular dividend
- $0.17 per share
- Q3 2025 regular quarterly cash dividend
- Q3 2025 revenue
- $21.2M
- Record third quarter 2025 revenue from prior earnings release
- Shares outstanding
- 12,721,156
- Common shares outstanding as of October 31, 2025
Historical Context
-
Board declared $0.50 per share special cash dividend on excess cash.
-
Named to TIME's America's Growth Leaders list, reflecting strong growth metrics.
-
Record Q3 2025 revenue, strong EPS, raised guidance and regular dividend.
-
Announcement of timing and access details for Q3 2025 earnings call.
-
Director retirement and appointment of new board member Joe Kiani.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
magnetic resonance imaging medical
mri medical
intravenous medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors (the “Board”) approved a special cash dividend of
“One of the Board’s commitments is maximizing returns to our stockholders. With our strong financial results over the years—including 17 consecutive quarters of record revenue—and our ability to generate cash from operations, our cash and cash equivalents balance grew to
The declaration and payment of any future dividends, whether regular quarterly dividends or special dividends, will remain subject to the sole discretion of the Board and will depend upon many factors, including but not limited to the Company’s financial condition, earnings, capital requirements, cash flows, liquidity needs, legal and regulatory requirements, general business conditions, growth opportunities, and other factors that the Board deems relevant. There can be no assurance that the Company will continue to pay regular quarterly dividends or declare any additional special dividends in the future.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in developing innovative MRI compatible medical devices and products. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.
We are the only known provider of a non-magnetic IV infusion pump system specifically designed for safe use during MRI procedures. We were the first to develop an infusion delivery system that effectively eliminates many of the risks and complications associated with MRI procedures. Standard infusion pumps contain magnetic and electronic components that can cause radio-frequency interference and are dangerous to operate near the powerful magnet used in an MRI system. Our patented MRidium® MRI-compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI-compatible patient vital signs monitoring system is designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, allowing it to operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from the critical care unit to the MRI and back, increasing patient safety through uninterrupted vital signs monitoring and reducing the time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and an optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system features an easy-to-use design and enables effective communication of patient vital signs information to clinicians.
For more information, please visit www.iradimed.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements, which involve risks and uncertainties, relate to analyses and other information that are based on forecasts of future results and estimates of amounts not yet determinable and may also relate to the Company’s future prospects, developments and business strategies. In particular, such forward-looking statements include the commercialization of the Company’s next-generation 3870 MRI IV pump that will drive additional growth in 2026 and beyond and the declaration and payment of any future dividends. These statements are based on our management’s current expectations and beliefs, as well as a number of assumptions concerning future events.
Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of the Company’s control that could cause actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties, assumptions and other important factors include, but are not limited to, those included in Part II, Item 1A, “Risk Factors” of the Company’s Quarterly Reports on Form 10-Q, and Part I, Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as those otherwise described or updated from time to time in our other filings with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Media Contact:
INVESTOR RELATIONS
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@Iradimed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.